Home Cart Sign in  
Chemical Structure| 1430213-30-1 Chemical Structure| 1430213-30-1

Structure of ML216
CAS No.: 1430213-30-1

Chemical Structure| 1430213-30-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML216 is a potent inhibitor of the DNA unwinding activity of BLM helicase, showing similar IC50s of 3.0 and 0.97 μM for full length BLM and BLM636–1298 respectively.

Synonyms: CID-49852229

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML216

CAS No. :1430213-30-1
Formula : C15H9F4N5OS
M.W : 383.32
SMILES Code : O=C(NC1=CC=C(F)C(C(F)(F)F)=C1)NC2=NN=C(S2)C3=CC=NC=C3
Synonyms :
CID-49852229
MDL No. :MFCD24849400
InChI Key :WMCOYUSJXXCHFH-UHFFFAOYSA-N
Pubchem ID :49852229

Safety of ML216

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ML216

DNA

Isoform Comparison

Biological Activity

Description
ML216 (CID-49852229) acts as a powerful, selective, and cell-penetrable blocker of BLM helicase's DNA unwinding function, exhibiting IC50 values of 2.98 μM for BLM full-length and 0.97 μM for BLM636-1298. Additionally, ML216 suppresses BLM's ssDNA-dependent ATPase activity with a Ki of 1.76 µM, displaying antitumor activity[1][2].
Target
  • helicase

    BLM636-1298, IC50:0.97 μM

    BLMfull-length, IC50:2.98 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
XG2 cell line 4.9 µM 48 and 96 hours ML216 induced cell cycle arrest and apoptosis Front Immunol. 2022 Dec 9;13:983181
XG19 cell line 1.2 µM 48 and 96 hours ML216 induced cell cycle arrest and apoptosis Front Immunol. 2022 Dec 9;13:983181
S18 ES cells (BL6 × SPRET F1 hybrid) 25 μM 5, 10, or 21 days induced recombination for genetic mapping, identified Hprt as the gene underlying 6-TG susceptibility Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3680-3685
BL6 × CAST F1 hybrid ES cells 25 μM induced mitotic recombination to generate homozygous genotypes Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3680-3685
mouse embryonic stem (ES) cells 25 μM 1 or 5 days inhibited BLM DNA helicase, induced random mitotic cross-overs, elevated homologous recombination rates Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3680-3685
CH3+5 HCT116 cells 8 μM 72 hours To evaluate the effect of ML216 on MMR-corrected HCT116 cells, results showed that ML216 had a weaker inhibitory effect on the growth of CH3+5 HCT116 cells. Proc Natl Acad Sci U S A. 2022 Dec 20;119(51):e2211775119
HCT116 cells 8 μM 72 hours To evaluate the inhibitory effect of ML216 on MSI CRC cells, results showed that ML216 significantly inhibited the growth of HCT116 cells and induced PUMA expression and apoptosis. Proc Natl Acad Sci U S A. 2022 Dec 20;119(51):e2211775119
human myeloma cell lines (HMCLs) 0.78 µM to 100 µM 4 days Evaluation of the inhibitory effect of ML216 on HMCLs proliferation, with a median IC50 of 2.78 µM Front Immunol. 2022 Dec 9;13:983181
PC3 cells 5 μM 48 hours To evaluate the inhibitory effects of ML216 combined with olaparib on the proliferation, clonogenicity, invasion, and migration of PC3 cells. Results showed that the combination treatment had stronger inhibitory effects compared to monotherapy. J Transl Med. 2023 Jul 6;21(1):445
A549 cells 2 µM 3 or 5 days To evaluate the proliferation inhibition and radiosensitization effects of ML216 on A549 cells. Results showed ML216 combined with olaparib significantly enhanced the radiosensitivity of A549 cells. Cancer Biol Med. 2021 Dec 1;19(8):1150–71
H1299 cells 2-10 µM 3 or 5 days To evaluate the proliferation inhibition and radiosensitization effects of ML216 on H1299 cells. Results showed ML216 significantly enhanced the radiosensitivity of H1299 cells. Cancer Biol Med. 2021 Dec 1;19(8):1150–71
H460 cells 2-10 µM 3 or 5 days To evaluate the proliferation inhibition and radiosensitization effects of ML216 on H460 cells. Results showed ML216 significantly enhanced the radiosensitivity of H460 cells. Cancer Biol Med. 2021 Dec 1;19(8):1150–71
IMR-90 cells 50 μM 24 hours To evaluate the effect of ML216 on DNA damage-induced senescence, results showed that ML216 significantly reduced the number of senescent cells. Cells. 2022 Dec 29;12(1):145
293T cells 0, 20, 50, or 100 μM 12 hours To evaluate the effect of ML216 on DBC1-BLM interaction, results showed that ML216 concentration-dependently increased the binding of BLM to DBC1. Cells. 2022 Dec 29;12(1):145
WPMY-1 cells 10 μM 48 hours Evaluate the inhibitory effect of ML216 and CDDP on WPMY-1 cell proliferation, showing no synergistic effect in combination therapy Molecules. 2022 Dec 12;27(24):8790
LNCap cells 10 μM 48 hours Evaluate the inhibitory effect of ML216 and CDDP on LNCap cell proliferation, showing that combination therapy has a stronger inhibitory ability Molecules. 2022 Dec 12;27(24):8790
22RV1 cells 10 μM 48 hours Evaluate the inhibitory effect of ML216 and CDDP on 22RV1 cell proliferation, showing that combination therapy has a stronger inhibitory ability Molecules. 2022 Dec 12;27(24):8790
PC3 cells 10 μM 48 hours Evaluate the inhibitory effect of ML216 and CDDP on PC3 cell proliferation, showing that combination therapy has a stronger inhibitory ability Molecules. 2022 Dec 12;27(24):8790
Plasmodium falciparum Dd2 1 nM to 1,000 μM 48 hours To evaluate the inhibitory effect of ML216 on parasite growth mSphere. 2020 Nov 25;5(6):e00956-20
XG1 cell line 13.2 µM 48 and 96 hours ML216 induced cell cycle arrest and apoptosis Front Immunol. 2022 Dec 9;13:983181

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCT116 xenograft tumors Intraperitoneal injection 1.5 mg/kg Daily for the first 7 days and then every other day for 13 days To evaluate the therapeutic effect of ML216 on MSI CRC xenograft tumors, results showed that ML216 significantly suppressed the growth of HCT116 tumors and increased TUNEL and active caspase 3 staining. Proc Natl Acad Sci U S A. 2022 Dec 20;119(51):e2211775119
BALB/c nude mice PC3 xenograft model Intraperitoneal injection 15 mg/kg/d Three times a week for 3 weeks To evaluate the inhibitory effects of ML216 combined with olaparib on the growth of PC3 xenograft tumors. Results showed that the combination treatment significantly reduced tumor volume and weight, with no observed toxicity in normal tissues. J Transl Med. 2023 Jul 6;21(1):445
BABL/c Nu/Nu male nude mice A549 xenograft model Subcutaneous injection 25 mg/kg/d 3 continuous days To evaluate the radiosensitization effects of ML216 combined with olaparib on A549 xenograft model. Results showed the combination significantly inhibited tumor growth and enhanced radiosensitivity. Cancer Biol Med. 2021 Dec 1;19(8):1150–71
C57BL/6J mice Naturally aged mouse model and bleomycin-induced idiopathic pulmonary fibrosis (IPF) mouse model Intraperitoneal injection 1 mg/kg (naturally aged model) and 0.5 mg/kg (IPF model) Twice a week for 5 weeks (naturally aged model) or 3 weeks (IPF model) To evaluate the effect of ML216 on senescence and fibrosis in vivo, results showed that ML216 significantly reduced the number of senescent cells, improved pulmonary function, and decreased the expression of fibrosis markers. Cells. 2022 Dec 29;12(1):145

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.04mL

2.61mL

1.30mL

26.09mL

5.22mL

2.61mL

References

 

Historical Records

Categories